Please assess the completion status of the following clinical trial:

Trial Title: Antibiotherapy During Therapeutic Hypothermia to Prevent Infectious Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years-old, intubated and mechanically ventilated after out-of-hospital resuscitated cardiac arrest secondary to shockable rhythm~* Hospitalized in an ICU~* Mild therapeutic hypothermia procedure (32° to 35°C) scheduled (24 to 36 hours)~* Delay from ROSC to randomisation \< 6 hours~* Consent from family members or emergency consent~Exclusion Criteria:~* Pregnancy~* Out-of-hospital cardiac arrest secondary to non shockable rhythm and In-hospital cardiac arrest~* Need for cardiac support by cardiopulmonary bypass~* Ongoing antibiotic therapy or during the week before~* Ongoing or concomitant pneumonia~* Known chronic colonization with MRB~* Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.~* History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).~* History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid, according to the latest version of the SmPC.~* Previous lung disease~* Predictable decision of early care limitation~* Patient under guardianship or curatorship~* Moribund patient~* Participation to another trial within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amoxicillin clavulanic acid (Type: EXPERIMENTAL): Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.

Based on this trial design, predict the completion outcome and termination type (if applicable).